Pay attention to baseline HBsAg…very low in this study…pegIFN alone in these type of patients with very low baseline HBsAg achieves functional cure rates as high as 30%.
In order to understand the true potential of these therapies, phase II trials must be conducted excluding patients with < 1000 IU/mL of HBsAg. The average HBsAg level in patients with chronic HBV infection is ~10,000 IU/mL.
yep. I saw that
16% (5/31) of participants demonstrated sustained HBsAg loss 24 weeks after end of treatment; Two of the five participants had baseline HBsAg levels greater than 1,000 IU/mL. No new safety findings were observed during the follow-up.
I’d like to know what exact numbers are those > 1000 